Browse News
Filter News
Found 52 articles
-
CAR T-Cell Therapy Market Demand is Set to Grow at 29.8% till 2032
8/24/2023
The global CAR T-Cell therapy market is evaluated at USD 3,827 million for the year 2022 and is projected to grow
-
Novotech Announced as Finalist for Asia Pacific Cell & Gene Therapy CRO Excellence Awards 2023
7/13/2023
Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities is a finalist in the Asia Pacific Cell & Gene Therapy Awards 2023.
-
Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity
6/22/2023
Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity.
-
Robotics in Healthcare Industry, Robots and Automation in Electronics Manufacturing, Deep Dive Analysis of 18+ Countries across 5 Key Regions, 50+ Companies Scrutinized in New Research Published by The Insight Partners
5/30/2023
The Insight Partners published latest research study on "Neurosurgical Robotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Component [Equipment/System (Robot Machines, Navigation System, Planner & Simulators, and Others), Accessories, and Services]
-
Cell and Gene Therapy Market Size To Expand USD 93.78 Bn By 2030
12/23/2022
The global cell and gene therapy market size was exhibited at USD 18.61 billion in 2022 and is expected to expand around USD 93.78 billion by 2030, poised to grow at a projected CAGR of 22.41% from 2022 to 2030.
-
Maryland Life Sciences Announces First Slate of Speakers for 2022 Bio Innovation Conference
9/14/2022
Maryland Life Sciences, a division of the Maryland Tech Council, is pleased to announce the first slate of speakers for its 2022 Bio Innovation Conference.
-
Pharmaceutical Robots Market to Witness Comprehensive Growth by 2026
6/22/2022
Wilmington, Delaware, United States: The global pharmaceutical robots market is expanding owing to a robust pharmaceutical industry and benefits offered by automation in this sector across the globe.
-
Cell And Gene Therapy Manufacturing Market Size to Worth Around US$ 67.4 Bn by 2030
6/1/2022
The global cell and gene therapy manufacturing market size is expected to be worth around US$ 67.4 billion by 2030, according to a new report by Vision Research Reports.
-
Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis
5/10/2022
Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, will present late-breaking interim data from its Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (MG) today at the 14th Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders.
-
Pharmaceutical Robots Market To Bag US$250.46 Mn By 2026, Large-scale Use in Scientific Research Propels Market Growth
4/22/2022
Albany NY, United States: The global pharmaceutical robots market is predicted in a report by Transparency Market Research to witness high adoption of regional expansion, new product development, and merger and acquisition as key business strategies.
-
Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma
1/25/2022
Cartesian Therapeutics today announced that it has dosed the first patient in a Phase 1/2a multicenter clinical study evaluating Descartes-25 in patients with multiple myeloma.
-
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies.
-
Cartesian Therapeutics Adds Five Internationally Recognized Experts to Board of Advisors
12/14/2021
Cartesian Therapeutics today announced the appointment of five internationally recognized Senior Advisors to support its growing clinical pipeline for autoimmune, respiratory, and inflammatory diseases.
-
Cartesian’s Descartes-08 is a new chimeric antigen receptor (CAR) - T cell therapy that strives to target the myasthenia gravis disease at its source.
-
BioSpace Movers & Shakers, Oct. 1
10/1/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
9/28/2021
Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the hire of Miloš Miljković, M.D., as Vice President and Chief Medical Officer.
-
Clinical Catch-Up: August 23-27
8/30/2021
It was a busy week for clinical trial news. Here’s a look. -
Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis
8/24/2021
Cartesian Therapeutics today announced clinical data from the first cohort of an ongoing Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (gMG). Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA).
-
Pharmaceutical Robots Market: Rising Need for Automation in Healthcare Industries to Boost Growth of the Market
5/20/2021
The global pharmaceutical robots market is predicted in a report by Transparency Market Research to witness high adoption of regional expansion, new product development, and merger and acquisition as key business strategies.
-
Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies
5/4/2021
Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced a $2 million competitive R&D award from the National Heart Lung and Blood Institute